Overview
SBFM market data
Price History
SBFM price chart · 1M
- O
- 1.22
- H
- 1.30
- L
- 1.18
- C
- 1.29
- Vol
- 8,060.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $1.22
- Previous Close
- $1.25
- Day High
- $1.30
- Day Low
- $1.18
- 52 Week High
- $23.05
- 52 Week Low
- $1.04
- 7 Day Return
- +12.17%
- 30 Day Return
- -9.79%
- 90 Day Return
- -49.90%
- 1 Year Return
- -86.43%
- Daily Notional Volume
- $10.4K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$14.37 Diluted earnings per share over the trailing twelve months.
- Beta
- -8.93 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -17.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.03 – $24.30 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.9M · P/B 0.26 · P/S 0.08.
Company News
Sunshine Biopharma Announces Updates On Its K1.1 mRNA Tumor Suppressor; Outlines Plans For ProgramBenzinga · Aug 26, 2026, 1:03 PM
EXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung CancerBenzinga · Aug 26, 2026, 12:31 PM
EXCLUSIVE: Sunshine Biopharma Reports Preclinical Tumor Suppression with K1.1 mRNA in Liver Cancer; Advances mRNA-Cancer Vaccine for Difficult-to-Treat Lung CancerBenzinga · Aug 26, 2026, 12:30 PM
Sunshine Biopharma Announces Approval Of Generic Enalapril Tablets 2.5mg, 5mg, 10mg And 20mg For Canadian MarketBenzinga · Aug 19, 2026, 1:02 PM
EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension DrugBenzinga · Aug 19, 2026, 12:30 PM
EXCLUSIVE: Sunshine Biopharma Receives Canadian Approval for Generic Enalapril for Hypertension in Four Dosage Strengths; Shipping To begin By Year-End 2026Benzinga · Aug 19, 2026, 12:30 PM
Sunshine Biopharma Announces Launch Of Generic Amoxicillin In Canada, Now Shipping To Pharmacies In Multiple Dosages And StrengthsBenzinga · Aug 7, 2026, 1:02 PM
Sunshine Biopharma shares are trading higher after the company announced the approval of its generic Dienogest tablets of 2mg for the Canadian market.Benzinga · Aug 4, 2026, 6:29 PM
EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug ApprovalBenzinga · Aug 4, 2026, 12:31 PM
EXCLUSIVE: Sunshine Biopharma Gets Canadian Regulatory Approval Of Generic Dienogest TabletsBenzinga · Aug 4, 2026, 12:30 PM